Bio Medica Laboratories L
✓Strengths
- Comfortable interest cover: operating profit covers interest about 10 times.
- Return on equity is healthy at 45.2%.
- Net profit margin is strong at 27.9%.
- Promoters hold a majority stake (67.7%).
!Watch-points
- Higher leverage: debt-to-equity of 1.54 is above 1.
These points are generated automatically from the company’s reported figures to highlight what stands out. They are descriptive observations for educational purposes only — not advice or a recommendation to buy, sell, or hold.
Forensic Checks
Altman Z-ScoreSafe zone
3.45
In Altman’s original study, companies in this range showed a low incidence of financial distress.
Computed without the working-capital term (current-asset split not available for this stock).
These are well-known academic screening models, shown for educational context only. They describe historical financial patterns and are not predictions, advice, or a recommendation to buy, sell, or hold.
Key Ratios
Market Cap₹ 199 Cr
Current Price—
High / Low₹ 181.00 / 102.00
Stock P/E16.60
Book Value—
Dividend Yield0.00%
ROCE—
ROE45.20%
Face Value₹ 10.00
Debt to Equity1.54
PEG Ratio—
EV / EBITDA11.38
Industry PE35.70
P/B Ratio—
EPS₹ 13.06
Debt₹ 40 Cr
PAT Margin27.91%
Cash PAT₹ 13 Cr
ICR10.00
Promoter Holding67.70%
FII Holding0.29%
DII Holding2.31%
Public Holding29.71%
Note on calculated ratios: where a value is not published in the source data, we compute it from the reported financials — Debt to Equity = total borrowings ÷ (equity capital + reserves); EV / EBITDA = (market cap + debt − cash) ÷ (operating profit + depreciation); PEG = P/E ÷ 3-year profit growth %. These may differ slightly from other sources that use different periods or TTM figures. Current Price, Market Cap and P/E reflect the live quote (cached 15 min).